Retrospective Analysis of the Results of Adjuvant Chemotherapy in Breast Cancer Patients with 10 or More Positive Nodes: Nonrandomized Comparison of Adriamycin-Containing Regimens

Jin Hee Ahn; Haeseoung Bahng; Jeong Gyun Kim; Sung Bae Kim; Sei Hyun Ahn; Hyesook Chang; Jung Shin Lee; Sang Hee Kim; Woo Kun Kim

doi:10.4143/crt.2002.34.2.84

Articles

Page Path: HOME > Cancer Res Treat > Volume 34(2); 2002 > Article

Retrospective Analysis of the Results of Adjuvant Chemotherapy in Breast Cancer Patients with 10 or More Positive Nodes: Nonrandomized Comparison of Adriamycin-Containing Regimens: Jin Hee Ahn, Haeseoung Bahng, Jeong Gyun Kim, Sung Bae Kim, Sei Hyun Ahn, Hyesook Chang, Jung Shin Lee, Sang Hee Kim, Woo Kun Kim; Cancer Research and Treatment 2002;34(2): 84-90.
DOI: https://doi.org/10.4143/crt.2002.34.2.84
Published online: April 30, 2002

¹Department of Medicine, Asan Medical Center, University ofUlsan College of Medicine, Seoul, Korea.
²Department of Surgery, Asan Medical Center, University ofUlsan College of Medicine, Seoul, Korea.
³Department of Radiation-Oncology, Asan Medical Center,University of Ulsan College of Medicine, Seoul, Korea.wkkim@amc.seoul.kr

3,988 Views
26 Download
1 Crossref
0 Scopus

prev next

Full Article

Download PDF

Abstract

PURPOSE
To evaluate the results of adriamycin-based adjuvant chemotherapy with or without high dose chemotherapy (HDC) with stem cell transplantation (SCT) in breast cancer with 10 or more positive axillary nodes.
MATERIALS AND METHODS
Seventy-one breast cancer patients who had undergone surgery and had 10 or more positive axillary nodes were included in this study held between January 1997 and December 1999. The pathologic and clinical records were reviewed retrospectively.
RESULTS
Twenty-nine patients were treated with adriamycin followed by 8 courses of CMF (group I); 22 patients received 4 courses of adriamycin and 7 patients received 3 courses of adriamycin. Twenty-six patients received median 6 courses of CAF (group II) and 16 patients underwent HDC and autologous SCT (group III). With a median follow-up of 27.1 months, relapses were observed in 24 patients (33.8%) and the 3-year disease-free survival (DFS) rate was 57.1%; group I/II 55.4%, and group III 62.7%. The three-year overall survival (OS) rate was 86.1%; group I/II 83.0%, group III 93.8%. There were no difference in the 3-year DFSs or in the OSs of group I and group II. However, patients who received only 3 courses of the sequential adriamycin in group I showed a significantly poorer 3-year OS than those that received 4 courses of adriamycin (42.9% vs. 95.5%).
CONCLUSION
Our study shows that adriamycin-containing combination chemotherapy is as effective as HDC with SCT in patients with 10 or more positive axillary lymph nodes judging by 3-year DFS and OS, and shows that three courses of adriamycin seems to be inadequate.

Keywords: Breast neoplasm;Adjuvant chemotherapy;Adriamycin;Stem cell transplantation

Figure & Data

References

Citations

Citations to this article as recorded by

Alternative Therapy and Abnormal Liver Function During Adjuvant Chemotherapy in Breast Cancer Patients
Jin-Hee Ahn, Sung-Bae Kim, Mi Ra Yun, Jung-Shin Lee, Yoon-Koo Kang, Woo Kun Kim
Journal of Korean Medical Science.2004; 19(3): 397. CrossRef

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Retrospective Analysis of the Results of Adjuvant Chemotherapy in Breast Cancer Patients with 10 or More Positive Nodes: Nonrandomized Comparison of Adriamycin-Containing Regimens

Cancer Res Treat. 2002;34(2):84-90. Published online April 30, 2002

DOI: https://doi.org/10.4143/crt.2002.34.2.84